@misc{10481/108173,
year = {2025},
month = {11},
url = {https://hdl.handle.net/10481/108173},
abstract = {Background/Objectives: Colorectal cancer (CRC) accounts for nearly 10% of global cancer
cases and is the second leading cause of cancer-related mortality. While age and genetics
are non-modifiable risk factors, nutrition and its impact on gut microbiota are emerging as
key determinants in CRC prevention and management. We aimed to systematically evaluate recent evidence on the role of diet and microbiota-targeted interventions—including
probiotics, prebiotics, synbiotics, and postbiotics—in modulating CRC risk and therapeutic
outcomes. Methods: A structured literature search was performed in PubMed, ResearchGate, Scopus, and ScienceDirect up to July of 2025. Reference lists of relevant reviews and
clinical trials were also screened. A total of 36 studies were selected according to PRISMA
guidelines. Data were extracted on dietary exposures, microbiota modulation, metabolite
profiles, and CRC-related outcomes. Evidence quality was assessed using appropriate
appraisal tools for observational and interventional designs. Results: Western-type diets
were consistently associated with microbiota dysbiosis, the enrichment of pro-inflammatory
and genotoxic taxa, and elevated CRC risk. Diets rich in fiber and polyphenols enhanced
commensals producing short-chain fatty acids (e.g., butyrate), with anti-inflammatory and
antineoplastic effects. Probiotics, prebiotics, and postbiotics demonstrated potential to restore microbial balance, improve epithelial integrity, and enhance tolerance to conventional
therapies. Conclusions: Current evidence supports a complex interplay between nutrition,
the gut microbiota, and CRC, with strong translational potential. Microbiota-modulating
nutritional strategies, particularly fiber-rich diets and synbiotics, show the most consistent
microbiota-related benefits in CRC prevention and represent promising adjuncts to standard therapies. However, much of the available research is still based on preclinical models.
Therefore, there is a pressing need for well-designed clinical studies in human populations
to validate these findings and inform evidence-based guidelines.},
organization = {Junta de Andalucía (CTS 164; PY20-01157; B-CTS-664-
UGR20)},
organization = {Junta de Andalucía - Instituto de Salud Carlos III - Ministerio de Ciencia e Innovación - Fondo Europeo de Desarrollo Regional (FEDER) (grants PI18/00826, PI20/01447, PI19/01058, PI24/02089, JDC2022-049478-I, CD23/00117, CD23/00142, IFI21/00030)},
publisher = {MDPI},
keywords = {microbiota},
keywords = {Colorectal cancer},
keywords = {Therapeutic approaches},
title = {Modulating Strategies of the Intestinal Microbiota in Colorectal Cancer},
doi = {10.3390/nu17223565},
author = {García Mansilla, María José and Rodríguez Sojo, María Jesús and Lista, Andreea Roxana and Ayala Mosqueda, Ciskey Vanessa and García García, Jorge and Gálvez Peralta, Julio Juan and Rodríguez Nogales, Alba and Ruiz Malagón, Antonio Jesús and Rodríguez Sánchez, María José},
}